TCS FY25 Annual Earnings Summary

North America revenue declined 1.1% YoY and BFSI remained negative YoY, with management citing ongoing client uncertainty and delayed decision-making.

A large life sciences client abruptly reduced scope, causing revenue decline. Recovery depends on client's future investment decisions.

Potential increase in inflation due to trade tariffs or uncertain government policies could dampen discretionary spending recovery.

Management noted project delays and cautious discretionary spending from late February; if uncertainty persists, deal conversions and revenue growth could be impacted.

Q1 TCV of $8.3B was below the $12.4B in Q4, with some large deals slipping to Q2, indicating volatility in deal closures.

Analyst questioned whether India's 61.8% YoY growth was largely BSNL-driven, raising concerns about sustainability of growth outside this deal.

Telecom and manufacturing verticals face structural headwinds; telecom due to CapEx caution, manufacturing due to labor and supply chain issues.

The BSNL deal revenue is at peak and expected to taper after Q3, potentially creating a growth headwind in H2.

Growth markets have lower margins; scaling them may pressure overall margins until volumes improve.

The BSNL contract tapering from Q4 could create a revenue gap; management is confident of replacement but execution risk remains.

North America revenue declined 2.3% YoY, and TTH slowed considerably in the US due to market-specific issues and strained client profitability.

Life sciences healthcare declined 4.3% YoY; recovery depends on policy clarity in the US, which is uncertain.